Figure 7: Interaction between CTLA-4 and tremelimumab.
From: Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
(a) Stereoview of the detailed CTLA-4/tremelimumab interface. The carbon atoms CTLA-4 and heavy and light chain of tremelimumab are coloured grey, green and purple, respectively. Hydrogen bonds and a salt bridge are indicated with dashed lines. (b) Surface representations of the CTLA-4 molecules in the complex structures of CTLA-4/B7-1 (left), CTLA-4/B7-2 (centre) and CTLA-4/tremelimumab (right). The surfaces of CTLA-4 in CTLA-4/B7-1 and CTLA-4/B7-2 are coloured grey and the B7-1 or B7-2 binding site on the surface of CTLA-4 is coloured orange. The surface of CTLA-4 in CTLA-4/tremelimumab is colored purple. The epitope regions for the heavy and light chain of tremelimumab are coloured blue and cyan, respectively.
